QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy QTI?
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QTI
Wall Street analysts forecast QTI stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.150
Low
Averages
High
Current: 7.150
Low
Averages
High
About QTI
QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QT Imaging Appoints New Senior Medical Advisor
- Advisor Appointment: QT Imaging has appointed Dr. Barry Roseman as Senior Medical Advisor, tasked with implementing QT Imaging technology in a busy breast diagnostic and screening center, which is expected to enhance clinical workflows and patient access.
- Clinical Experience Contribution: With over 5,000 breast cancer patients treated in his career, Dr. Roseman's involvement will provide critical clinical and operational insights that will drive the evolution of breast imaging workflows.
- Technology Validation: Dr. Roseman's decision to deploy the QTI Breast Acoustic CT scanner in his clinical setting not only validates QT Imaging's mission but also underscores the importance of new technologies in breast cancer screening.
- Patient-Centric Focus: QT Imaging aims to improve breast health management through radiation-free, compression-free 3D imaging technology, and Dr. Roseman's engagement will help advance this goal, particularly for women with dense breast tissue.
See More
QT Imaging to Report Q1 2026 Financial Results on May 13
- Earnings Announcement Schedule: QT Imaging will report its financial results for the three months ended March 31, 2026, after market close on May 13, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: The company will hold an investor conference call at 4:30 PM ET on the same day, providing real-time updates and enhancing interaction with investors, which is expected to attract significant market attention.
- Pre-Registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN, streamlining the dial-in process and reflecting the company's focus on improving user experience.
- Technological Innovation Focus: QT Imaging is dedicated to developing low-frequency sound wave imaging systems aimed at improving global health outcomes, emphasizing its strategic importance in safe, affordable, and patient-centered medical imaging.
See More
QT Imaging Launches New Breast Imaging Technology for Enhanced Clinical Efficiency
- Technological Innovation: QT Imaging has launched the QT Imaging-Olea Viewer in collaboration with Olea Medical, which integrates multiple breast imaging modalities to enhance clinical efficiency and support more comprehensive patient management, expected to significantly improve the quality of breast health management.
- Data Integration: The platform combines QTscan data with mammography, digital breast tomosynthesis, MRI, and ultrasound, enhancing diagnostic confidence and providing clinicians with improved interpretive capabilities, which is anticipated to lead to better treatment outcomes for patients.
- Radiation-Free Imaging: The Breast Acoustic CT system from QT Imaging utilizes advanced ultrasound technology to deliver 3D imaging without radiation, particularly beneficial for women with dense breast tissue, expected to offer a safer imaging option for this specific demographic.
- Future Development: The QT Imaging-Olea Viewer will be showcased at the SBI Breast Imaging Symposium in Seattle from April 16-19, 2026, marking the company's ongoing innovation and potential for market expansion in the breast imaging sector.
See More
QT Imaging CEO Participates in Women's Change Celebration
- Increased Focus on Women's Health: QT Imaging's CEO Dr. Raluca Dinu spoke at Harvard's Shiftmakers Gala, emphasizing the importance of early breast cancer detection, particularly for nearly half of U.S. women and 70-80% of women in Asia with dense breast tissue, highlighting the company's commitment to improving breast health management.
- Promotion of Innovative Technology: QT Imaging's Breast Acoustic CT™ technology will be featured in an upcoming issue of The Shift, aiming to spread critical information about early breast cancer detection to a broader audience of women, thereby enhancing public awareness and importance of breast health.
- Expanded Industry Influence: The event, supported by notable figures like Gloria Steinem, not only enhances QT Imaging's brand image but also showcases its leadership in women's health, potentially attracting more investor attention.
- Future Development Strategy: Dr. Dinu noted that women's health is gaining national attention, and QT Imaging plans to leverage this trend to drive technological innovation and market expansion, ensuring better detection outcomes and patient experiences while reducing gaps in women's health management.
See More
QT Imaging Releases Next-Gen Reconstruction Software Enhancing Breast Imaging
- Image Quality Improvement: QT Imaging's latest version 4.5.0 reconstruction software significantly enhances spatial resolution in reflection imaging by implementing optimized spatially varying deconvolution, resulting in more accurate image representation while maintaining processing efficiency, thereby improving clinical image usability and interpretability.
- Expanded Clinical Applications: The new software version improves image reconstruction for small breasts and provides more accurate assessments of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and broadening the software's usability across diverse patient anatomies, thus enhancing clinical decision support capabilities.
- Multimodal Imaging Advancement: QT Imaging is advancing the development of attenuation as an additional quantitative biomarker, complementing speed of sound and reflection intensity, which is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support.
- Commitment to Continuous Innovation: These technological advancements reflect QT Imaging's ongoing focus on improving image quality, clinical reliability, and workflow efficiency, marking another significant step in the company's development of advanced imaging software solutions aimed at enhancing global health outcomes.
See More
QT Imaging Files $100M Mixed Securities Shelf Registration
- Securities Shelf Filing: QT Imaging has filed a $100 million mixed securities shelf registration, which, while not an offer to sell, indicates the company's active engagement in capital markets and may pave the way for future financing opportunities.
- Financial Performance: The company reported a GAAP EPS of -$0.10 and revenue of $8.28 million, and despite the losses, QT Imaging reaffirmed its FY26 outlook, demonstrating confidence in future growth prospects.
- Preliminary Financial Data: Preliminary figures show a GAAP EPS of -$0.10 with revenue slightly increasing to $8.3 million, indicating the company's stability in the market, although it still faces challenges in achieving profitability.
- Quant Rating Insight: Seeking Alpha's Quant Rating on QT Imaging provides context with historical financial data, revealing that despite current underperformance, there remains a divergence in market perceptions regarding the company's future potential.
See More
QT Imaging Appoints New Senior Medical Advisor
- Advisor Appointment: QT Imaging has appointed Dr. Barry Roseman as Senior Medical Advisor, tasked with implementing QT Imaging technology in a busy breast diagnostic and screening center, which is expected to enhance clinical workflows and patient access.
- Clinical Experience Contribution: With over 5,000 breast cancer patients treated in his career, Dr. Roseman's involvement will provide critical clinical and operational insights that will drive the evolution of breast imaging workflows.
- Technology Validation: Dr. Roseman's decision to deploy the QTI Breast Acoustic CT scanner in his clinical setting not only validates QT Imaging's mission but also underscores the importance of new technologies in breast cancer screening.
- Patient-Centric Focus: QT Imaging aims to improve breast health management through radiation-free, compression-free 3D imaging technology, and Dr. Roseman's engagement will help advance this goal, particularly for women with dense breast tissue.
See More
QT Imaging to Report Q1 2026 Financial Results on May 13
- Earnings Announcement Schedule: QT Imaging will report its financial results for the three months ended March 31, 2026, after market close on May 13, 2026, demonstrating the company's commitment to transparency and investor communication.
- Investor Conference Call: The company will hold an investor conference call at 4:30 PM ET on the same day, providing real-time updates and enhancing interaction with investors, which is expected to attract significant market attention.
- Pre-Registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN, streamlining the dial-in process and reflecting the company's focus on improving user experience.
- Technological Innovation Focus: QT Imaging is dedicated to developing low-frequency sound wave imaging systems aimed at improving global health outcomes, emphasizing its strategic importance in safe, affordable, and patient-centered medical imaging.
See More
QT Imaging Launches New Breast Imaging Technology for Enhanced Clinical Efficiency
- Technological Innovation: QT Imaging has launched the QT Imaging-Olea Viewer in collaboration with Olea Medical, which integrates multiple breast imaging modalities to enhance clinical efficiency and support more comprehensive patient management, expected to significantly improve the quality of breast health management.
- Data Integration: The platform combines QTscan data with mammography, digital breast tomosynthesis, MRI, and ultrasound, enhancing diagnostic confidence and providing clinicians with improved interpretive capabilities, which is anticipated to lead to better treatment outcomes for patients.
- Radiation-Free Imaging: The Breast Acoustic CT system from QT Imaging utilizes advanced ultrasound technology to deliver 3D imaging without radiation, particularly beneficial for women with dense breast tissue, expected to offer a safer imaging option for this specific demographic.
- Future Development: The QT Imaging-Olea Viewer will be showcased at the SBI Breast Imaging Symposium in Seattle from April 16-19, 2026, marking the company's ongoing innovation and potential for market expansion in the breast imaging sector.
See More
QT Imaging CEO Participates in Women's Change Celebration
- Increased Focus on Women's Health: QT Imaging's CEO Dr. Raluca Dinu spoke at Harvard's Shiftmakers Gala, emphasizing the importance of early breast cancer detection, particularly for nearly half of U.S. women and 70-80% of women in Asia with dense breast tissue, highlighting the company's commitment to improving breast health management.
- Promotion of Innovative Technology: QT Imaging's Breast Acoustic CT™ technology will be featured in an upcoming issue of The Shift, aiming to spread critical information about early breast cancer detection to a broader audience of women, thereby enhancing public awareness and importance of breast health.
- Expanded Industry Influence: The event, supported by notable figures like Gloria Steinem, not only enhances QT Imaging's brand image but also showcases its leadership in women's health, potentially attracting more investor attention.
- Future Development Strategy: Dr. Dinu noted that women's health is gaining national attention, and QT Imaging plans to leverage this trend to drive technological innovation and market expansion, ensuring better detection outcomes and patient experiences while reducing gaps in women's health management.
See More
QT Imaging Releases Next-Gen Reconstruction Software Enhancing Breast Imaging
- Image Quality Improvement: QT Imaging's latest version 4.5.0 reconstruction software significantly enhances spatial resolution in reflection imaging by implementing optimized spatially varying deconvolution, resulting in more accurate image representation while maintaining processing efficiency, thereby improving clinical image usability and interpretability.
- Expanded Clinical Applications: The new software version improves image reconstruction for small breasts and provides more accurate assessments of fibroglandular tissue composition in breasts with implants, addressing important clinical scenarios and broadening the software's usability across diverse patient anatomies, thus enhancing clinical decision support capabilities.
- Multimodal Imaging Advancement: QT Imaging is advancing the development of attenuation as an additional quantitative biomarker, complementing speed of sound and reflection intensity, which is expected to further enhance tissue characterization capabilities and provide clinicians and researchers with additional quantitative information for improved analysis and decision support.
- Commitment to Continuous Innovation: These technological advancements reflect QT Imaging's ongoing focus on improving image quality, clinical reliability, and workflow efficiency, marking another significant step in the company's development of advanced imaging software solutions aimed at enhancing global health outcomes.
See More
QT Imaging Files $100M Mixed Securities Shelf Registration
- Securities Shelf Filing: QT Imaging has filed a $100 million mixed securities shelf registration, which, while not an offer to sell, indicates the company's active engagement in capital markets and may pave the way for future financing opportunities.
- Financial Performance: The company reported a GAAP EPS of -$0.10 and revenue of $8.28 million, and despite the losses, QT Imaging reaffirmed its FY26 outlook, demonstrating confidence in future growth prospects.
- Preliminary Financial Data: Preliminary figures show a GAAP EPS of -$0.10 with revenue slightly increasing to $8.3 million, indicating the company's stability in the market, although it still faces challenges in achieving profitability.
- Quant Rating Insight: Seeking Alpha's Quant Rating on QT Imaging provides context with historical financial data, revealing that despite current underperformance, there remains a divergence in market perceptions regarding the company's future potential.
See More
